<p>美國銀行證券分析師 Alec Stranahan 昨日重申了對 Agios Pharma 的買入評級，並設定了 41.00 美元的目標價。該公司股票昨日收於 28.42 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票創意，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>Stranahan 覆蓋醫療保健行業，關注 Moderna、Beam Therapeutics 和 Revolution Medicines 等股票。根據 TipRanks 的數據，Stranahan 的平均回報率為 10.3%，推薦股票的成功率為 52.78%。</p>
<p>除了美國銀行證券，Agios Pharma 還在 4 月 30 日獲得了 Truist Financial 的 Gregory Renza 的買入評級。然而，在 4 月 29 日，RBC Capital 對 Agios Pharma（納斯達克：AGIO）維持了持有評級。</p>

Agios制藥

<p>美國銀行證券分析師 Alec Stranahan 重申了對 Agios Pharma（AGIO）的買入評級，目標價為 41.00 美元，而該股收盤價為 28.42 美元。專注於醫療保健行業的 Stranahan 平均回報率為 10.3%，成功率為 52.78%。此外，Agios Pharma 還獲得了 Truist Financial 的買入評級，而 RBC Capital 則維持了持有評級</p>

<p>Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Agios Pharma yesterday and set a price target of $41.00. The company’s shares closed yesterday at $28.42.</p>
<div class="lb-trans"><p>美國銀行證券分析師 Alec Stranahan 昨日重申了對 Agios Pharma 的買入評級，並設定了 41.00 美元的目標價。該公司股票昨日收於 28.42 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票創意，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>Stranahan covers the Healthcare sector, focusing on stocks such as Moderna, Beam Therapeutics, and Revolution Medicines. According to TipRanks, Stranahan has an average return of 10.3% and a 52.78% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Stranahan 覆蓋醫療保健行業，關注 Moderna、Beam Therapeutics 和 Revolution Medicines 等股票。根據 TipRanks 的數據，Stranahan 的平均回報率為 10.3%，推薦股票的成功率為 52.78%。</p>
</div><p>In addition to Bank of America Securities, Agios Pharma also received a Buy from Truist Financial’s Gregory Renza in a report issued on April 30. However, on April 29, RBC Capital maintained a Hold rating on Agios Pharma (NASDAQ: AGIO).</p>
<div class="lb-trans"><p>除了美國銀行證券，Agios Pharma 還在 4 月 30 日獲得了 Truist Financial 的 Gregory Renza 的買入評級。然而，在 4 月 29 日，RBC Capital 對 Agios Pharma（納斯達克：AGIO）維持了持有評級。</p>
</div>

Bank of America Securities Sticks to Their Buy Rating for Agios Pharma (AGIO)

Tip Ranks

美國銀行

Moderna

Beam Therapeutics

Revolution Medicines

Truist Financial

加拿大皇家銀行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

美國銀行證券維持對 Agios 製藥（AGIO）的買入評級